US SEC Filings Daily Market Digest — October 13, 2026

13-10-2026

Regentis Biomaterials reported strong surgeon interest in its CE Mark-approved GelrinC® knee cartilage implant at the 8th ICRS Summit in Porto, Portugal (October 8–10, 2026). The company highlighted a Phase II result of approximately 100% greater KOOS improvement versus historical microfracture controls at two years, and noted its U.S. FDA pivotal Phase III trial has completed over 50% enrollment. The release is promotional in nature and contains no reported financial results, revenue, or quantified commercial metrics.

• · Company is listed on NYSE American under ticker RGNT
• · Company's Annual Report on Form 20-F was filed with the SEC on February 24, 2026
• · GelrinC requires no cell harvesting or laboratory processing and is described as cell-free and off-the-shelf
• · The release contains no financial results, revenue figures, or cash position data

13-10-2026

Central Puerto S.A. (CEPU) filed a 6-K disclosing share and ADR purchases made on October 9, 2026, with trade completion on October 13, 2026. The filing reports a purchase of 120,000 CPSA shares on BYMA at an average price of AR$ 2,037.49 for a total cash amount of AR$ 244,499,775, and a purchase of 30,000 Proener ADRs on NYSE (equivalent to 300,000 underlying shares) at an average price of USD 12.69 for a total of USD 380,764.92. The filing does not indicate whether these are open-market buybacks by the company or purchases by a related party, and it contains no period-over-period financial comparison.

• · Proener ADR average price of USD 12.69 implies an equivalent per-share price of roughly USD 1.27 (30,000 ADRs equal 300,000 underlying shares, a 10:1 ADR ratio)
• · Trade date 10/09/2026 and trade completion date 10/13/2026 indicate a settlement lag of two business days between execution and completion

13-10-2026

KE Holdings Inc. (BEKE) furnished a Form 6-K for October 2026 that serves as a transmittal of five Next Day Disclosure Returns (Exhibits 99.1 through 99.5) dated October 5 through October 9, 2026. The filing body itself contains no financial results, operational metrics, or substantive content beyond the exhibit index and signature by CFO XU Tao. Substantive details would reside in the referenced exhibits, which are not included in the provided text.

• · Exhibits 99.1-99.5 cover Next Day Disclosure Returns dated October 5, 6, 7, 8, and 9, 2026 respectively
• · Commission File Number 001-39436; principal executive offices in Haidian District, Beijing, PRC
• · Registrant files annual reports on Form 20-F

13-10-2026

KT Corp's Board of Directors resolved on October 13, 2026 to set October 28, 2026 as the record date for shareholders entitled to a quarterly dividend under Article 49-2 of the company's Articles of Incorporation. The resolution was approved with all 7 outside directors present and none absent, and no dividend amount is disclosed in this filing.

• · Record date for quarterly dividend entitlement is October 28, 2026
• · Shareholders of record will be determined by the record date without closing the shareholders' register
• · The Audit Committee is composed entirely of independent directors

13-10-2026

SSR Mining Inc. filed a Form 8-K on October 13, 2026 furnishing a news release announcing the results of a 2026 Technical Report Summary (TRS) for its Marigold Complex in Nevada, prepared under Subpart 1300 of Regulation S-K. The filing also files the full TRS (Exhibit 99.1) with the qualified person's consent (Exhibit 23.1) and notes that the company will use its corporate website as a channel for Regulation FD material disclosures. The filing contains no quantitative financial results, reserve figures, or period-over-period comparisons in the text provided.

• · Filing is furnished under Item 7.01 (not deemed 'filed' for Exchange Act Section 18 purposes) and the TRS is filed under Item 8.01
• · Exhibits include the TRS (99.1), the qualified person consent (23.1), the news release (99.2), and the Inline XBRL cover page (104)
• · Securities registered on Nasdaq under symbol SSRM; the company is incorporated in British Columbia and headquartered in Denver, Colorado
• · Company designates its investor relations website (ir.ssrmining.com) as a channel for material information under Regulation FD

13-10-2026

AmpliTech Group, Inc. (AMPGW) has filed its DEF 14A proxy statement for the Annual Meeting of Stockholders to be held December 1, 2026 at 5:00 p.m. Eastern Time in Hauppauge, New York. Stockholders of record as of October 9, 2026 (30,127,415 shares outstanding) will vote on the election of five directors and the ratification of Sadler, Gibb & Associates, LLC as the independent registered public accounting firm for fiscal year 2026. The Board recommends voting FOR both proposals; the filing contains no reported financial performance results.

• · Proposal No. 1 (election of five directors) requires a plurality vote; withheld votes and broker non-votes have no effect on outcome.
• · Proposal No. 2 (auditor ratification) requires a majority of votes cast; it is treated as a routine matter, so no broker non-votes are expected.
• · Notice of Internet Availability of Proxy Materials is being mailed on or about October 15, 2026.
• · Voting deadline is 11:59 p.m. Eastern Time on November 30, 2026 for internet, fax, email, and mail voting.
• · Registration for in-person attendance opens at 4:00 p.m. Eastern Time; attendance is first-come, first-served and space is limited.
• · Designated proxy holders are Fawad Maqbool (CEO) and Louisa Sanfratello (CFO).

13-10-2026

Aegon Ltd. filed a 6-K reporting the transcript of its October 8, 2026 extraordinary general meeting, at which shareholders approved a redomiciliation to Delaware (renaming to Transamerica Inc.) and an Omnibus Incentive Plan, with 64% of issued capital present or represented. The redomiciliation is expected to take effect on or about January 1, 2028, with the exchange of common shares B into common shares on a 40-to-1 basis scheduled for October 15, 2026. Management highlighted strong Transamerica first-half 2026 growth (operating results up 10% YoY, operating capital generation up 35%, gross remittances up 18%), while shareholder questions focused on unresolved risks around SEC Rule 14A-8, M&A discipline, and IFRS-to-U.S. GAAP transition staffing.

• · Redomiciliation effectiveness expected on or about January 1, 2028; exchange of common shares B scheduled for October 15, 2026, when interim bylaws take effect
• · Management intends to report under U.S. GAAP for full-year 2027 and provide U.S. GAAP KPIs at a December 2027 Capital Markets Day
• · New York Stock Exchange to become primary listing, with shares also trading on Euronext
• · Governance changes include phased annual director elections, a single class of common stock with equal voting rights, preferred stock authorization, majority voting with resignation policy, and elimination of the two-thirds voting requirement
• · Omnibus plan includes double-trigger change-in-control vesting, no liberal share recycling, no repricing of options without shareholder approval, no dividends on unvested equity, and a fixed share reserve with no evergreen provision
• · Management expects annual burn rate below 1%, though this depends on assumptions about pending U.S. recruitment
• · Unresolved shareholder concerns: management declined to commit to shareholder engagement before future board bylaw amendments beyond general principles, declined to take a position on SEC Rule 14A-8 changes, and did not commit to assessing share-funded acquisitions against intrinsic value rather than market price
• · Management did not provide specific M&A preconditions, performance measure disclosure commitments, or quantified U.S. GAAP transition milestones
• · Finance and risk staffing in the Netherlands must be retained through the transition, with retention programs in place; Aegon is recruiting in the U.S. across finance, risk, legal, and compliance

13-10-2026

Fusion Fuel Green PLC filed a 6-K furnishing unaudited consolidated financial statements for the six months ended June 30, 2026 and 2025, plus unaudited pro forma combined information with Royal Uranium Inc. The company closed its share exchange acquisition of Royal Uranium on July 21, 2026, issuing 3,750,018 Class A Ordinary Shares for all 81,881,029 Royal Uranium common shares, which values Royal Uranium at $15,000,000 and makes it a wholly-owned subsidiary. The filing also discloses that FY2025 audited financials were restated (Form 20-F/A filed October 6, 2026) and that prior pro forma information should no longer be relied upon.

• · Closing of the Royal Uranium share exchange occurred July 21, 2026, after a June 11, 2026 amendment that adjusted Royal Uranium share counts and reduced the share issuance.
• · FY2025 audited consolidated financial statements (Form 20-F filed May 7, 2026) were restated; the Audit Committee concluded on September 25, 2026 they should no longer be relied upon, with the restated 20-F/A filed October 6, 2026.
• · Pro forma financial information for FY2025 furnished in a July 29, 2026 6-K/A does not reflect the restatement and should no longer be relied upon.
• · The Advisory Agreements (dated February 12, 2026) may require additional Class A Ordinary Shares or pre-funded warrants to Advisors if certain conditions are met, so further dilution is possible.
• · The 6-K is incorporated by reference into multiple Form F-3 and Form S-8 registration statements.

13-10-2026

Sphera Funds Management Ltd. and its affiliated entities (Sphera Global Healthcare GP Ltd. and Sphera Global Healthcare Management LP) filed an amended Schedule 13G reporting beneficial ownership of 2,663,296 shares of Tenax Therapeutics, Inc. common stock, representing 7.09% of the class as of September 30, 2026. The reported position includes 127,600 shares underlying call options exercisable within 60 days, and the filing is a passive Rule 13d-1(c) disclosure with no stated intent to influence control.

• · Position is held under Rule 13d-1(c) and certified as not acquired or held for the purpose of or with the effect of changing or influencing control of the issuer.
• · Sphera Funds Management Ltd. owns 90% of Sphera Global Healthcare GP Ltd., which manages the Management Company.
• · The filing reports the group may be deemed a Section 13(d) group, but the reporting persons disclaim the existence of any group.
• · The filing is an amendment to a prior Schedule 13G (joint filing agreement referenced as filed August 27, 2026), and the document's stated filing date is October 13, 2026 while signatures are dated October 8, 2026.

13-10-2026

Domino's Pizza reported Q3 2026 results with global retail sales growth of 3.2% excluding FX, total revenues up 3.4% to $1,185.6 million, and income from operations up 8.3% to $241.8 million. Diluted EPS rose 12.7% to $4.60, aided by share buybacks. However, U.S. same store sales grew only 0.3%, international same store sales (ex-FX) grew just 0.2%, and free cash flow declined 7.2% over the three fiscal quarters to $459.8 million.

• · U.S. Company-owned same store sales grew 1.0% in Q3 2026, down from 3.4% a year earlier
• · U.S. franchise same store sales grew 0.3% in Q3 2026, down from 5.3% a year earlier
• · Three-quarter U.S. same store sales grew 0.4%, down from 2.7% in the prior-year period
• · International same store sales (ex-FX) were negative (-0.1%) for the three fiscal quarters of 2026 versus +2.5% a year earlier
• · Net income grew only 1.8% over three fiscal quarters ($427.7M vs $420.1M), and three-quarter diluted EPS rose 4.7%
• · Free cash flow decline attributed to timing of advertising payments and unfavorable changes in operating assets and liabilities
• · Revenue growth was partly offset by lower U.S. Company-owned store revenues following Q2 2026 refranchising
• · Quarterly dividend of $1.99 per share payable December 30, 2026 to holders of record as of December 15, 2026
• · Company's leverage ratio of 4.2x is within its historical 4-6x operating range

13-10-2026

SS Innovations International, Inc. (SSII) entered into a Securities Purchase Agreement dated October 9, 2026 with Growth Capital Partners, LLC for a Secured Convertible Promissory Note with an original principal amount of $21,025,000.00, for a cash purchase price of $20,000,000.00 after a $1,000,000.00 original issue discount, plus a $25,000.00 transaction expense payment. The note is guaranteed by five subsidiaries and secured by a Security Agreement and an Intellectual Property Security Agreement, and it is convertible into common shares, which are to be registered under an effective Form S-3 shelf with a 424B prospectus supplement due within five Trading Days of closing. The filing contains no period-over-period financial results, so no balanced performance comparison is available; the terms impose ongoing SEC-reporting, listing, and dilution-related restrictions on the company.

• · Note is convertible into common shares ($0.0001 par value) and is secured by a Security Agreement and an Intellectual Property Security Agreement executed by SSI IP Holdings, Inc.
• · Company agreed to covenants including maintaining SEC reporting, keeping shares listed on NYSE, NYSE American, or Nasdaq, avoiding trading halts, and refraining from Restricted Issuances without Investor consent.
• · Company must not sell or pledge equity in subsidiaries or issue additional subsidiary equity without restriction.
• · Closing Date is October 9, 2026 or a mutually agreed date; governing law and venue are Utah, and the Company indemnifies Investor against unpaid broker fees.
• · Filing contains a representation that the Company has not been a Shell Company in the prior twelve months and that its SEC reports since January 1, 2025 were timely filed.

13-10-2026

Sino Green Land Corporation entered into a Debt-to-Equity Conversion Agreement on September 30, 2026, converting US$2,400,528 of unsecured, non-interest-bearing demand loans owed to controlling persons and related creditors into 4,801,056 shares of common stock at a fixed price of US$0.50 per share. The conversion fully extinguishes the loans and releases the Company from related claims, with the shares issued under Section 4(a)(2) and/or Regulation D or Regulation S exemptions.

• · The L&W Creditors and the Empower Creditor are controlling persons of the Company or entities controlled by controlling persons, making this a related-party transaction.
• · Loans were cancelled and extinguished in full upon closing on September 30, 2026, with each creditor releasing the Company from all claims relating to its loan.
• · Shares were issued in reliance on Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D or Regulation S, and are subject to transfer restrictions and restrictive legends.
• · The Company's common stock trades under the symbol SGLA on OTC Markets.

13-10-2026

Zhihu Inc. furnished a 6-K filing dated October 13, 2026 consisting of a set of Hong Kong Stock Exchange regulatory disclosures. The package includes Next Day Disclosure Returns dated October 5, 6, 7, 8 and 9, 2026, plus a Monthly Return on movements in securities for an equity issuer with Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules. The filing is administrative in nature and contains no quantitative financial results in the exhibit index itself.

• · Filing covers Next Day Disclosure Returns for October 5 through October 9, 2026 (Exhibits 99.1, 99.2, 99.4, 99.5, 99.6).
• · Exhibit 99.3 is a Monthly Return on Movements in Securities for an issuer with Hong Kong Depositary Receipts listed under Chapter 19B.
• · The exhibit index alone does not disclose the substantive content of the Next Day Disclosure Returns, so specific transaction details cannot be verified from this text.

13-10-2026

Humana entered a new joint venture with funds managed by HPS Investment Partners (a BlackRock subsidiary) to operate its CenterWell Senior Primary Care clinics, replacing existing WCAS joint ventures and removing the WCAS put option, which the company expects to significantly reduce associated balance sheet liabilities and lower its cost of capital. Humana affirmed FY 2026 Adjusted EPS guidance of at least $9.00, but flagged that GAAP EPS guidance may change due to the liability reduction and other strategic initiatives, and that Q3 2026 financial close is still in progress.

• · CenterWell may begin purchasing clinics from the joint venture at its election starting in 2028
• · If CenterWell has not acquired all clinics by end of 2033, BlackRock may elect to exit via sale process, subject to CenterWell's right of first offer
• · The new arrangement includes no BlackRock put option and minimum return protections for BlackRock, which create a derivative instrument recorded at fair value on the balance sheet
• · Guidance was previously issued July 29, 2026 and affirmed in 8-Ks filed September 1, 2026 and October 9, 2026
• · Company cannot yet reconcile FY 2026 Adjusted EPS guidance to GAAP diluted EPS without unreasonable effort because Q3 2026 close is incomplete

13-10-2026

ASE Technology Holding reported monthly net revenues for September 2026 of NT$88,130 million (US$2,777 million), up 7.2% sequentially from August and 45.5% year-over-year in NT$ terms. Third-quarter 2026 net revenues reached NT$244,161 million (US$7,642 million), up 27.8% quarter-over-quarter and 44.8% year-over-year. The filing discloses figures for two reporting segments; the second segment's September revenue growth was more modest sequentially (+2.7% in NT$) than the first segment's, even though both posted strong year-over-year gains.

• · Segment 1 September revenue growth slowed to +7.2% sequentially in NT$ and +8.7% in US$, while Segment 2 grew only +2.7% sequentially in NT$ (+4.2% in US$) month over month.
• · Segment 2 Q3 2026 sequential growth (+20.1% NT$) trailed Segment 1 (+27.8% NT$), indicating uneven momentum between the two segments.
• · Currency translation contributed to the gap between NT$ and US$ growth rates; NT$ growth rates exceed US$ growth rates in every period shown, reflecting NT$ depreciation against the US dollar relative to the comparison periods.

13-10-2026

High Roller Technologies (ROLR) filed a Regulation FD 8-K clarifying that an internal marketing email sent in error on October 9, 2026 incorrectly suggested the launch of its prediction markets product during the week of October 12, 2026. The Company states no launch date has been announced or set, and reaffirms its prior expectation of a launch in October 2026, on a date to be confirmed.

• · An email sent in error by the marketing department on Friday, October 9, 2026 to a select group of individuals implied a launch during the week of October 12, 2026
• · No public launch date has been announced and none has been set
• · Company reiterates prior guidance of a prediction markets launch in October 2026, date to be confirmed
• · Filing is furnished under Item 7.01 (Regulation FD) and includes forward-looking statement risk factors covering product development delays and changes in the prediction markets regulatory environment

13-10-2026

IX Acquisition Corp. convened and adjourned its extraordinary general meeting in lieu of an annual general meeting on October 7, 2026, with shareholders approving the Fifth Extension Amendment Proposal and the Auditor Ratification Proposal. Quorum was met with approximately 66.17% of issued and outstanding ordinary shares present or represented. In connection with the vote, 435,000 shares were tendered for redemption.

• · The Meeting was adjourned to October 9, 2026 at 12:00 p.m. Eastern Time (the filing text references 2025 in one place, which appears to be a typo)
• · The Proxy Statement was filed with the SEC and first mailed to shareholders on or about September 25, 2026
• · Only 13 votes were cast against the Fifth Extension Amendment Proposal, indicating near-unanimous support

13-10-2026

IonQ entered a definitive agreement to acquire Elisity, Inc., a Zero Trust security company, in an all-stock transaction valued at up to $1.3 billion, including up to $150 million in earnout opportunity tied to Elisity's performance. The deal is expected to close in Q4 2026, subject to customary conditions and required regulatory approval. Management highlights Elisity's rapid historical growth (revenue and customer base doubling year-over-year, zero churn among deployed customers) and access to the more-than-$10 billion microsegmentation market, while the filing itself provides no Elisity revenue figures or IonQ financial impact beyond the deal value.

• · Share issuance price collar: IonQ shares priced at 20-day VWAP but capped at $49.61 and floored at $33.07 per share
• · Elisity will continue under current leadership including CEO James Winebrenner after closing
• · Filing references a White House Executive Order dated June 22, 2026 on quantum innovation and federal PQC migration as context for the deal
• · Elisity founded in 2019 with a global employee footprint and a growing number of Fortune 500 customers
• · Deal financial impact on IonQ earnings or revenue is not quantified in the filing; Elisity's standalone revenue is not disclosed

13-10-2026

Zhanling International Ltd (ZLME) reported a net loss of $6,597 for the three months ended August 31, 2026, versus $8,126 in the prior-year quarter, a 18.8% reduction in losses, with general and administrative expenses as the sole operating cost. The company holds no cash, total assets of $3,404 (all prepayments), and a stockholders' deficit that widened to $(59,636) from $(53,039) at May 31, 2026, with total liabilities rising to $63,040 driven by new amounts due to related and non-related parties. The filing shows continued going-concern-type financial stress, with the balance sheet relying on related-party funding to cover expenses.

• · Cash balance was zero at both August 31, 2026 and 2025; all operating costs were funded by related and non-related party advances and expenses paid on the company's behalf.
• · Weighted average shares outstanding rose about 23.7% year over year (2,782,000 to 3,441,000), reflecting conversion of payables to equity of $12,368 in the current quarter.
• · Current-period liabilities shifted from non-current to current: $46,900 of non-current related/non-related party debt at May 31, 2026 is now classified as current due to related parties ($53,668) and non-related parties ($5,600).
• · Prepayments rose from $183 to $3,404, consuming operating cash flow adjustments of $3,221 in the quarter.

13-10-2026

ArriVent BioPharma, Inc. (AVBP) disclosed via Form 8-K (Items 7.01, 8.01, 9.01) that it dosed its first patient in the U.S. Phase 1 trial of ARR-002, a potential first-in-class MUC16/NaPi2b dual-target tetravalent antibody-drug conjugate for ovarian and endometrial cancer. The announcement is furnished under Regulation FD and attached as Exhibit 99.1; the filing contains no financial results or quantitative figures.

• · ARR-002 is described as a potential first-in-class MUC16/NaPi2b dual-target tetravalent antibody-drug conjugate
• · Target indications are ovarian and endometrial cancer
• · Filing is made under Regulation FD; the information is furnished, not filed, under Section 18 of the Exchange Act
• · Company is an emerging growth company; common stock trades on Nasdaq under AVBP

13-10-2026

Adagio Medical Holdings, Inc. (ADGM) filed a definitive proxy statement (DEF 14A) dated October 13, 2026 for a virtual Special Meeting of Stockholders on October 23, 2026 at 8:00 a.m. Pacific Time. The sole substantive proposal asks stockholders to approve alternate amendments to the Certificate of Incorporation authorizing a reverse stock split at a ratio between 1-for-10 and 1-for-500, with the final ratio at the Board's sole discretion. Record date is October 5, 2026, and the filing discloses no financial performance data for the period.

• · Stockholders of record as of October 5, 2026 are entitled to vote; log-in opens 7:45 a.m. PT on October 23, 2026
• · Internet and telephone voting closes 8:59 p.m. Pacific Time on October 22, 2026
• · Up to 15 minutes are allotted for stockholder Q&A at the conclusion of the meeting
• · Shares not voted by stockholders of record are not counted; returned proxies without selections default to 'For' Proposal No. 1
• · Filing fee: no fee required (checked on Schedule 14A cover)

13-10-2026

Charter Communications, Inc. (CCO Holdings Capital Corp. is a co-registrant) disclosed that Adam Ray will step down as Executive Vice President and Chief Commercial Officer, effective October 12, 2026, after 21 years with the company. He will remain employed in a non-executive advisory capacity through December 31, 2026, and his departure is treated as a termination without cause, subject to a separation and release agreement. The filing discloses continued vesting of certain equity awards and extended option exercisability, but it does not name a successor or quantify the severance amounts.

• · Departure is treated as a termination without cause, triggering severance and benefits under Mr. Ray's employment agreement, subject to a separation and release agreement
• · Portions of unvested time-based RSUs and stock options will continue vesting over the original schedule as if employment had not ended, subject to the release
• · Vested stock options remain exercisable for up to 60 months after the later of the Departure Date and the applicable vesting date, not exceeding the option expiration date
• · The filing does not identify a successor Chief Commercial Officer

13-10-2026

New Oriental Education & Technology Group Inc. (NYSE: EDU) filed a Form 6-K for October 2026 furnishing Exhibit 99.1, an announcement of the date of a board meeting. The filing is procedural and contains no financial results, operating metrics, or guidance, so no period-over-period performance can be assessed.

• · The filing is a Form 6-K report of a foreign private issuer for the month of October 2026, with the company headquartered at No. 6 Hai Dian Zhong Street, Haidian District, Beijing.
• · The company files annual reports on Form 20-F, as indicated by the cover page check box.
• · The substantive content is Exhibit 99.1, an announcement of the date of a board meeting; the exhibit text itself (meeting date and agenda) is not reproduced in the provided content.

13-10-2026

Drilling Tools International Corp's subsidiary Drilling Tools International Holdings, Inc. has engaged a Norwegian investment bank to arrange fixed income investor meetings in the Nordic market starting October 14, 2026, ahead of a possible U.S. dollar-denominated senior secured bond issue. Proceeds would partly finance the previously announced acquisition of Saltire Energy Limited, repay the existing term loan in full and a portion of the asset-based revolving credit facility, and fund general corporate purposes. The filing is a Rule 135c notice; the bond issue is not yet launched, is subject to market conditions, and no dollar amount is disclosed.

• · Investor meetings are scheduled to begin October 14, 2026, in the Nordic fixed income market.
• · Bonds will be offered only to qualified institutional buyers under Rule 144A and to non-U.S. persons under Regulation S, and will not be registered under the Securities Act.
• · The filing is made under Rule 135c and is not an offer to sell or a solicitation of an offer to buy securities.
• · Forward-looking statements flag the risk that the bond issue is not completed on the anticipated terms or at all.

13-10-2026

ImmuCell Corporation reported preliminary, unaudited Q3 2026 total sales of $8.0 million, up 46.0% YoY, with domestic sales of $6.9 million (up 29.2%). Nine-month total sales reached $25.6 million, up 27.8% YoY. Management noted that Q3 2025 comparisons were depressed by high distributor purchases in Q2 2025, and the company will discontinue early sales reporting in favor of full quarterly reporting.

• · Q3 2025 comparison base was depressed by high distributor purchases in Q2 2025, which flatters the reported 46% growth rate
• · Management attributes growth to sales team expansion, improved commercial execution, and better ability to reliably manufacture product to meet demand
• · Full quarterly results, including revenue, financial metrics, and market/distribution data, will be discussed on a conference call on November 13, 2026 at 9:00 AM ET
• · Management is discontinuing preliminary sales releases going forward, in line with standard SEC reporting practices

13-10-2026

Tower Semiconductor announced that it will release its third quarter 2026 financial results on Monday, November 2, 2026, and hold a conference call that day at 10:00 a.m. Eastern Time to discuss those results and fourth quarter 2026 guidance. The call will be webcast via the company's Investor Relations website, with pre-registration required for dial-in access. The filing contains no quantitative financial results.

• · Conference call scheduled for 10:00 a.m. Eastern Time (5:00 p.m. Israel time) on November 2, 2026
• · Company operates one 200mm facility in Israel, two 200mm facilities in the U.S., and two facilities in Japan (200mm and 300mm), plus a shared 300mm facility in Agrate, Italy with STMicroelectronics
• · Filed under Form 20-F designation as a foreign private issuer

13-10-2026

Enlight Renewable Energy Ltd. (ENLT) announced via Form 6-K that it will release its financial results for the third quarter ended September 30, 2026 before the opening of the Tel Aviv Stock Exchange on Tuesday, November 3, 2026. CEO Adi Leviatan and management will host English (8:00am ET) and Hebrew (6:00am ET) conference calls and webcasts, with an accompanying investor presentation. This filing is a scheduling and logistics notice and contains no reported financial figures.

• · Q3 2026 results release date: Tuesday, November 3, 2026, prior to the Tel Aviv Stock Exchange open
• · English conference call and webcast at 8:00am Eastern Time / 3:00pm Israel Time
• · Hebrew webcast at 6:00am Eastern Time / 1:00pm Israel Time
• · Investor materials and archived English webcast to be posted on the company's IR website

13-10-2026

Perpetual Ltd, an Australian asset manager (Sydney), filed a Form 13F-HR reporting its U.S.-listed equity holdings as of September 30, 2026, submitted October 13, 2026. The filing lists a large portfolio of U.S. common stocks across sectors including technology, energy, utilities, and financials, with major positions in names such as Alphabet, Amazon, Apple, Broadcom, Chevron, and Carnival. The excerpt provided is truncated, so aggregate portfolio value and period-over-period changes cannot be verified from the content given.

• · Filing is a 13F-HR for the period ending September 30, 2026, with a non-U.S. filer address in Sydney, New South Wales, Australia
• · Holdings are reported across multiple investment discretion categories (SOLE and SHARED-DEFINED/DFND by manager numbers 1 through 4), indicating shared investment authority across affiliated managers
• · Sample position sizes range from a few hundred shares to multi-million-share stakes, e.g., 2,397,259 CNH Industrial shares and 3,931,084 Baker Hughes shares, with many larger notional values disclosed in dollar terms in the information table
• · The filing covers a broad U.S. equity universe spanning technology, healthcare, energy, mining, utilities, and consumer names

13-10-2026

Liberty Defense Holdings, Ltd. furnished a Form 6-K for October 2026, attaching Exhibit 99.1, a press release dated October 12, 2026. The filing itself contains only the cover page, exhibit index, and signature block, signed by CEO William Frain, so no operating, financial, or regulatory details are disclosed in the document text provided. The substantive content resides in the referenced press release, which was not included in the supplied content.

• · Filing references Exhibit 99.1, a press release dated October 12, 2026, which is not included in the provided content
• · Registrant files annual reports on Form 20-F (Form 40-F box not checked)
• · Principal executive office listed at 187 Ballardvale Street, Suite 110, Wilmington, Massachusetts 01887
• · Commission File Number 001-43241

13-10-2026

ClearOne, Inc. (NASDAQ: CLRO) received a Nasdaq Staff determination letter on October 8, 2026 that it failed to satisfy the $2.5 million minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1), after not completing remedial actions in its compliance plan submitted May 22, 2026. Nasdaq has determined to delist the company's common stock, but the company intends to request a hearing before a Nasdaq Hearings Panel by October 15, 2026, which would automatically stay suspension; absent a timely hearing request, trading would be suspended at the open on October 19, 2026. The filing contains no quantitative financial results and is negative in tone with significant uncertainty about the outcome.

• · Nasdaq initially notified the company on April 7, 2026 of non-compliance with Listing Rule 5550(b); a compliance plan deadline of May 22, 2026 applied, and Nasdaq granted an exception through October 5, 2026
• · Hearing request deadline is October 15, 2026; trading suspension would occur at the open on October 19, 2026 if no hearing is requested
• · The company states there is no assurance Nasdaq will grant a hearing or that it will regain compliance
• · The company's FY2025 Form 10-K was filed March 31, 2026 and is referenced for risk factors

13-10-2026

WOODSTOCK CORP (CIK 0001008877, Boston, MA) filed a Form 13F-HR on October 13, 2026 reporting its institutional equity holdings as of September 30, 2026. The information table lists 160 holdings with a reported total portfolio value of approximately $1,244,910,317,000 (as stated in the cover page 'Table Value Total' field, reproduced exactly from the filing). Largest positions by reported value include NVIDIA Corp (~$106.4B), Microsoft Corp (~$82.0B), Apple Inc (~$55.0B), Alphabet Inc Class C (~$48.9B), and O'Reilly Automotive (~$47.2B). The filing is a routine quarterly disclosure and does not itself indicate a trading decision, acquisition, or regulatory action.

• · Filing covers period ending September 30, 2026 and was filed October 13, 2026 (accession 0001062993-26-005277).
• · Reported holdings are concentrated in mega-cap technology: NVIDIA, Microsoft, Apple, Alphabet, and Amazon together account for a large share of the reported table value.
• · Holdings include a mix of individual equities, ETFs (e.g., iShares Russell Mid-Cap, Vanguard FTSE Emerging Markets, State Street SPDR S&P 500), and several small-cap or speculative names (e.g., Aldeyra Therapeutics, Poet Technologies, Eyepoint, Bicycle Therapeutics).
• · Several positions show partial 'Other Managers' sole-discretion splits, with the bulk held under SOLE voting authority.

13-10-2026

Evernorth Holdings Inc. filed an 8-K furnishing an October 12, 2026 press release that announces a new Chief Investment Officer and corrects the share count issued at the October 9, 2026 closing of its business combination with Armada Acquisition Corp. II. Delayed Funding Subscribers received 1,078,613 Class A shares, not the 663,510 reported in the prior 8-K due to a clerical error, and several related share counts in that filing change accordingly. Total Class A shares outstanding at closing are 23,638,882 and Class C shares are 31,392,746; former SPAC public shareholders hold 20.5% of outstanding Class A common stock.

• · Filing corrects a clerical error: Delayed Funding Subscribers received 1,078,613 Class A shares, not 663,510 as previously reported
• · Corrected share count changed multiple figures in the prior 8-K, including outstanding Class A shares and Sponsor-related holdings
• · Delayed funding amounts could be settled in cash or XRP tokens, converted at $10.00 per share
• · Sponsor holds 92.5% of Class C Common Stock; SBI Holdings holds 7.5%
• · Sponsor shares voting and disposition control of 4,215,479 Class A shares with RippleWorks Inc.

13-10-2026

BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced via an 8-K filing dated October 13, 2026 (event date October 6, 2026) that the FDA accepted its New Drug Application (NDA) for oral infigratinib for children with achondroplasia and granted Priority Review. The filing itself contains no quantitative financial results; the substantive content is incorporated by reference from Exhibit 99.1, the press release. No dollar amounts, percentages, or period-over-period financial metrics are disclosed in the filing.

• · Priority Review designation typically implies an FDA review clock of about six months from filing acceptance, versus standard review, though the exact PDUFA target date is not disclosed in this filing
• · Filing is limited to Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits); no financial statements are included

13-10-2026

Prudential PLC disclosed daily share repurchase activity on the London Stock Exchange (XLON) for the five trading days from 5 to 9 October 2026, with aggregate purchases ranging from 787,614 to 817,174 shares per day (roughly 4.0 million shares in total). Volume-weighted average prices (VWAP) ranged from 8.8304 to 9.2517, with prices dipping sharply on 7 to 8 October before partially recovering on 9 October; the filing reflects ongoing buyback execution rather than a new program announcement.

• · Lowest daily price was 8.7340 on 8 October 2026, the period low.
• · Highest daily price was 9.2960 on 6 October 2026, the period high.
• · Daily share purchases were consistent, all between roughly 788,000 and 817,000 shares, despite the price decline on 7 and 8 October.
• · Filing discloses trading venue only as XLON; no purchases on other venues are reported in this table.

13-10-2026

Zenas BioPharma, Inc. (ZBIO) furnished a press release on October 12, 2026 under Regulation FD announcing new data from its Phase 3 trial of obexelimab in immunoglobulin G4-related disease (IgG4-RD), including open label extension data. The filing itself contains no quantitative financial results, and the underlying trial results are contained only in the furnished Exhibit 99.1, which was not included in the provided content.

• · Filing made under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Exhibit 99.1 press release and Exhibit 104 cover page XBRL)
• · Common stock (par value $0.0001) trades on The Nasdaq Global Select Market under symbol ZBIO
• · Company is an emerging growth company headquartered in Waltham, MA
• · Information is furnished, not filed, and is not subject to Section 18 liabilities of the Exchange Act

13-10-2026

Flex Ltd. filed a DEFA14A additional proxy communication dated October 13, 2026, concerning a proposed spin-off of a business to be named Axiom Solutions International, Inc. ("Axiom"). Flex previously filed a Schedule 14A proxy statement on October 5, 2026 seeking shareholder approval of the spin-off-related proposals, and Axiom has filed a Form 10 registration statement covering its common stock. The communication is principally a legal and disclosure notice directing investors to the proxy statement, Form 10, and related SEC filings, with no quantitative financial results disclosed.

• · Flex filed a Schedule 14A proxy statement with the SEC on October 5, 2026, seeking shareholder approval of spin-off-related proposals
• · Axiom Solutions International, Inc. has filed a Form 10 registration statement with the SEC for its common stock
• · Shareholders are directed to read the proxy statement and Form 10 in full; investor documents are available on the SEC website and at investors.flex.com

13-10-2026

United Microelectronics Corporation (UMC) furnished a Form 6-K report of foreign issuer dated October 13, 2026, filed under Rule 13a-16 of the Securities Exchange Act of 1934. The filing is a cover-and-signature document signed by CFO Chitung Liu, with an exhibit index referencing Exhibit 99, a substantive 6K disclosure whose content is not reproduced in the filing text provided. No financial figures, performance metrics, or event details are contained in the available text.

• · Commission File Number: 001-15128
• · Registrant address: No. 3 Li-Hsin 2nd Road, Hsinchu Science Park, Hsinchu, Taiwan, R.O.C.
• · Exhibit 99 ('6K on 10/13/2026') is referenced in the exhibit index but its substantive content is not included in the provided text; the actual disclosure subject matter cannot be determined from this filing alone

13-10-2026

Mitesco, Inc. received a $25,000 face-value 10% original issue discount convertible bridge note from historical investor ZSP Capital, LLC, requiring repayment of $27,500 at maturity in 12 months and convertible at $0.15 per share. The company also issued 2,000,000 restricted shares (500,000 each to four individuals) as compensation for assistance on its TCDC edge computing data center and Robo Agent software projects, valued at $0.0375 per share, bringing shares outstanding to approximately 51 million. Director Dr. Jordan Ballencic resigned on October 8, 2026, citing lack of time, and the Board will not fill the vacancy; the company continues acquisition discussions and restructuring of its bridge notes and Series A Preferred shares.

• · The 2026 Bridge Note is a 10% original issue discount convertible promissory note, meaning the company receives less than the face amount of repayment obligation.
• · Board vacancy from Dr. Ballencic's resignation will not be filled, despite the company's stated acquisition efforts, reducing board size.
• · Shares were issued under Section 4(a)(2) private placement exemption, so the shares are restricted and not freely tradable.
• · Filing discloses ongoing restructuring of existing Bridge notes and Series A Preferred shares, signaling balance sheet pressure not quantified in the filing.

13-10-2026

MiniMed Group, Inc. (MMED) held its 2026 Annual Meeting of Stockholders on October 9, 2026, where all four proposals were approved. Stockholders elected four Class I directors (Kevin E. Lofton, David J. Endicott, D. Keith Grossman, and Timothy (Tim) A. Wicks) to serve until the 2029 Annual Meeting, ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal year ending April 30, 2027, and approved executive compensation on an advisory basis. The company will hold future say-on-pay votes annually, following the one-year frequency preferred by stockholders.

• · Each director nominee received roughly 99% or more of votes cast in favor, with David J. Endicott receiving the highest support (approximately 99.7% for vs. withheld).
• · Say-on-pay frequency vote: a strong majority (approximately 276.2 million votes) favored an annual vote, with only minimal support for two- or three-year frequencies.
• · Advisory say-on-pay passed with very few votes against (approximately 91,742).

13-10-2026

VinFast reported preliminary domestic Vietnam deliveries of 23,624 EVs in September 2026, up 17% month-over-month, with year-to-date deliveries of 177,697 units (an average of roughly 20,000 per month). The VF 3 was the best-selling model in September with 6,474 units, followed by the Limo Green at 5,027. Results exclude vehicles sold in Vietnam under agreements providing for later export and remain subject to change after the year-end audit.

• · Deliveries are domestic Vietnam only and exclude vehicles sold locally under agreements for later export, so they do not capture VinFast's international volumes
• · The company explicitly states delivery figures are not a reliable indicator of quarterly financial results, which depend on average selling price and cost components
• · The VF 6 at 3,083 units is the only top-five model in September not highlighted with a cumulative figure beyond nine months; the VF 8 and VF 7 volumes (1,494 and 1,092) are the lowest in the monthly ranking

13-10-2026

This 6-K filing from Caledonia Mining Corporation Plc contains only an enquiries/contacts section listing investor relations, Nomad and broker, financial PR, and sponsor contacts across the UK and Zimbabwe. The excerpt contains no financial results, operational updates, or material corporate developments, so no substantive performance metrics can be assessed from the provided content.

• · Cavendish Capital Markets Limited acts as Nomad and Broker; IH Securities (Private) Limited acts as VFEX Sponsor in Zimbabwe
• · The filing provides contact details for UK and Zimbabwe-based advisers and public relations firms but no operational or financial content

13-10-2026

EON Resources Inc. (NYSE American: EONR) determined on October 8, 2026 that its 2025 Form 10-K, filed September 28, 2026, should no longer be relied upon due to an error in calculating depletion, depreciation and amortization (DD&A) expense for Q4 2025. The error overstated FY2025 DD&A by $3,540,000, and the net loss decreased by $2,632,000; the reported loss attributable to shareholders is expected to fall from $10.1 million to approximately $7.5 million in an amended 10-K. The restatement is non-cash and does not affect cash flows or cash and marketable investments.

• · The restatement affects only the FY2025 Form 10-K filed with the SEC on September 28, 2026; the company will file an amended 10-K and restate subsequent interim periods.
• · Figures are preliminary and remain subject to completion of the restatement analysis, financial close, and audit/review procedures.
• · Management discussed the matters with its independent registered accounting firm, CBIZ CPAs P.C.
• · The company is an emerging growth company, and the filing is made under Item 4.02 (Non-Reliance on Previously Issued Financial Statements).

13-10-2026

Quetta Acquisition Corporation (QETAR), a Delaware SPAC, held a special meeting on October 9, 2026, where stockholders approved an extension amendment pushing its deadline to complete an initial business combination from October 10, 2026 to October 10, 2027 (extendable monthly, with a $5,000 trust deposit per extension). Holders of 1,550,843 shares redeemed for an aggregate of approximately $18.4 million, leaving only 149,860 shares outstanding. The vote passed with 2,486,760 votes for and 525,980 against.

• · Roughly 96% of the 3,747,748 shares outstanding did not remain in the company after redemptions, leaving 149,860 shares
• · Extension permits the deadline to be moved up to a date set by the Board of Directors, not only through the full twelve-month period
• · Company intends to file the charter amendment with the Delaware Secretary of State

13-10-2026

Starry Sea Acquisition Corp (SSEAR), a Cayman Islands SPAC, postponed its extraordinary general meeting from October 9, 2026 to October 19, 2026 to allow more time to engage with shareholders. Based on the redemption tabulation as of October 7, 2026, 4,281,993 public shares were submitted for redemption, leaving 1,468,007 public shares outstanding, and the company is seeking to reverse redemption requests on about 350,174 shares to reach at least 1,818,181 outstanding shares so the $60,000 monthly extension cap does not reduce the per-share contribution.

• · Filed under Item 7.01 (Regulation FD) and Item 8.01 (Other Events); the company furnished this as soliciting material under Rule 14a-12, tied to the upcoming shareholder vote
• · Per-share extension contribution is $0.033, and at the current 1,468,007 public shares the implied monthly contribution would be well below the $60,000 cap, which is why the company is pursuing reversals
• · The original redemption deadline was October 7, 2026, and the meeting was rescheduled from 10:00 a.m. to 9:00 a.m. Eastern Time on October 19, 2026

13-10-2026

Duos Technologies Group (DUOT) disclosed the appointment of Christopher DeAlmeida as Chief Financial Officer, effective August 24, 2026, and Matthew Polimeni as Chief Legal Officer, effective September 8, 2026. Both executives signed three-year employment agreements with a $350,000 base salary, an 80% target bonus, and a grant of 200,000 restricted shares vesting in 2029 with change-of-control acceleration. The filing does not disclose any financial performance metrics.

• · Polimeni previously served as Deputy General Counsel of APR Energy (2020-2026) and Associate General Counsel of Duos (2025-2026) during the APR Energy Asset Management Agreement with Duos
• · Polimeni previously served as General Counsel and Chief of Staff of The HCI Group (2017-2020) and as an Assistant State Attorney in Florida's Fourth Judicial Circuit
• · DeAlmeida agreement signed October 4, 2026 but effective August 24, 2026; Polimeni agreement signed October 2, 2026 but effective September 8, 2026 (retroactive effective dates)
• · Non-renewal of either agreement is treated as termination without Cause, triggering severance
• · No family relationships or Item 404(a) related-party transactions involving Polimeni are disclosed

13-10-2026

CCO and GC Wang Yanjun sold 757 Class A ordinary shares at $95.47 (~$72.3K). 6 transactions reported in total. Wang Yanjun holds 81,780 shares after the transaction. Trades executed under a Rule 10b5-1 plan.

• · CCO and GC Wang Yanjun sold 204 Class A ordinary shares at $94.82 (~$19.3K)
• · CCO and GC Wang Yanjun sold 757 Class A ordinary shares at $95.47 (~$72.3K)
• · CCO and GC Wang Yanjun sold 39 Class A ordinary shares at $96.19 (~$3.75K)
• · CCO and GC Wang Yanjun sold 312 Class A ordinary shares at $95.32 (~$29.7K)
• · CCO and GC Wang Yanjun sold 668 Class A ordinary shares at $96.10 (~$64.2K)
• · CCO and GC Wang Yanjun sold 20 Class A ordinary shares at $96.87 (~$1.94K)